DexCom Statistics
Total Valuation
DexCom has a market cap or net worth of $34.31 billion. The enterprise value is $34.67 billion.
| Market Cap | 34.31B |
| Enterprise Value | 34.67B |
Important Dates
The next confirmed earnings date is Thursday, February 13, 2025, after market close.
| Earnings Date | Feb 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
DexCom has 390.60 million shares outstanding. The number of shares has decreased by -2.90% in one year.
| Current Share Class | 390.60M |
| Shares Outstanding | 390.60M |
| Shares Change (YoY) | -2.90% |
| Shares Change (QoQ) | -1.58% |
| Owned by Insiders (%) | 0.35% |
| Owned by Institutions (%) | 96.24% |
| Float | 387.69M |
Valuation Ratios
The trailing PE ratio is 52.67 and the forward PE ratio is 46.32. DexCom's PEG ratio is 1.93.
| PE Ratio | 52.67 |
| Forward PE | 46.32 |
| PS Ratio | 8.80 |
| Forward PS | 7.66 |
| PB Ratio | 17.52 |
| P/TBV Ratio | 18.70 |
| P/FCF Ratio | 64.62 |
| P/OCF Ratio | 42.08 |
| PEG Ratio | 1.93 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 41.26, with an EV/FCF ratio of 64.81.
| EV / Earnings | 50.93 |
| EV / Sales | 8.77 |
| EV / EBITDA | 41.26 |
| EV / EBIT | 55.21 |
| EV / FCF | 64.81 |
Financial Position
The company has a current ratio of 2.46, with a Debt / Equity ratio of 1.31.
| Current Ratio | 2.46 |
| Quick Ratio | 2.03 |
| Debt / Equity | 1.31 |
| Debt / EBITDA | 2.97 |
| Debt / FCF | 4.84 |
| Interest Coverage | 33.05 |
Financial Efficiency
Return on equity (ROE) is 32.06% and return on invested capital (ROIC) is 8.21%.
| Return on Equity (ROE) | 32.06% |
| Return on Assets (ROA) | 6.06% |
| Return on Capital (ROIC) | 8.21% |
| Revenue Per Employee | $411,875 |
| Profits Per Employee | $70,917 |
| Employee Count | 9,600 |
| Asset Turnover | 0.61 |
| Inventory Turnover | 2.60 |
Taxes
In the past 12 months, DexCom has paid $63.10 million in taxes.
| Income Tax | 63.10M |
| Effective Tax Rate | 8.48% |
Stock Price Statistics
The stock price has decreased by -27.53% in the last 52 weeks. The beta is 1.13, so DexCom's price volatility has been higher than the market average.
| Beta (5Y) | 1.13 |
| 52-Week Price Change | -27.53% |
| 50-Day Moving Average | 79.21 |
| 200-Day Moving Average | 91.58 |
| Relative Strength Index (RSI) | 69.50 |
| Average Volume (20 Days) | 3,350,853 |
Short Selling Information
The latest short interest is 8.80 million, so 2.25% of the outstanding shares have been sold short.
| Short Interest | 8.80M |
| Short Previous Month | 9.33M |
| Short % of Shares Out | 2.25% |
| Short % of Float | 2.27% |
| Short Ratio (days to cover) | 2.73 |
Income Statement
In the last 12 months, DexCom had revenue of $3.95 billion and earned $680.80 million in profits. Earnings per share was $1.67.
| Revenue | 3.95B |
| Gross Profit | 2.44B |
| Operating Income | 628.00M |
| Pretax Income | 806.90M |
| Net Income | 680.80M |
| EBITDA | 840.40M |
| EBIT | 628.00M |
| Earnings Per Share (EPS) | $1.67 |
Balance Sheet
The company has $2.49 billion in cash and $2.59 billion in debt, giving a net cash position of -$98.90 million or -$0.25 per share.
| Cash & Cash Equivalents | 2.49B |
| Total Debt | 2.59B |
| Net Cash | -98.90M |
| Net Cash Per Share | -$0.25 |
| Equity (Book Value) | 1.98B |
| Book Value Per Share | 5.07 |
| Working Capital | 2.53B |
Cash Flow
In the last 12 months, operating cash flow was $821.70 million and capital expenditures -$286.70 million, giving a free cash flow of $535.00 million.
| Operating Cash Flow | 821.70M |
| Capital Expenditures | -286.70M |
| Free Cash Flow | 535.00M |
| FCF Per Share | $1.37 |
Margins
Gross margin is 61.68%, with operating and profit margins of 15.88% and 17.22%.
| Gross Margin | 61.68% |
| Operating Margin | 15.88% |
| Pretax Margin | 18.81% |
| Profit Margin | 17.22% |
| EBITDA Margin | 21.25% |
| EBIT Margin | 15.88% |
| FCF Margin | 13.53% |
Dividends & Yields
DexCom does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 2.90% |
| Shareholder Yield | 2.90% |
| Earnings Yield | 1.97% |
| FCF Yield | 1.55% |
Analyst Forecast
The average price target for DexCom is $99.29, which is 13.05% higher than the current price. The consensus rating is "Buy".
| Price Target | $99.29 |
| Price Target Difference | 13.05% |
| Analyst Consensus | Buy |
| Analyst Count | 17 |
| Revenue Growth Forecast (5Y) | 13.89% |
| EPS Growth Forecast (5Y) | 22.53% |
Stock Splits
The last stock split was on June 13, 2022. It was a forward split with a ratio of 4:1.
| Last Split Date | Jun 13, 2022 |
| Split Type | Forward |
| Split Ratio | 4:1 |
Scores
DexCom has an Altman Z-Score of 7.59 and a Piotroski F-Score of 5.
| Altman Z-Score | 7.59 |
| Piotroski F-Score | 5 |